Wealthfront Advisers
SLS icon

Wealthfront Advisers’s SELLAS Life Sciences SLS Stock Holding History

Wealthfront Advisers’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$588K Buy
39,822
+28,386
+248% +$196K ﹤0.01% 829
2026
Q1 		$48.4K Buy
+11,436
New +$51.2K ﹤0.01% 1064

Other funds holding SLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Wealthfront Advisers's SLS Position: Q2 2026 in Review

Wealthfront Advisers increased its SELLAS Life Sciences (SLS) stake by 248% in Q2 2026, buying an estimated $196K and bringing the position to 39,822 shares worth $588K. The position accounts for ﹤0.01% of the portfolio, ranked #829.

Wealthfront Advisers first reported a position in SLS in Q1 2026 and has held it in 2 quarters since. 192 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

  • Wealthfront Advisers held 39,822 shares of SELLAS Life Sciences worth $588K as of Q2 2026.
  • Wealthfront Advisers bought 28,386 SELLAS Life Sciences shares in Q2 2026, an estimated $196K.
  • SELLAS Life Sciences made up ﹤0.01% of Wealthfront Advisers's portfolio in Q2 2026, its #829 holding.
  • Wealthfront Advisers first reported a position in SELLAS Life Sciences in Q1 2026 and has held it in 2 quarters since.
  • 192 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on Wealthfront Advisers's 13F filing for Q2 2026, filed 7 Aug 2026.